Market revenue in 2023 | USD 12.7 million |
Market revenue in 2030 | USD 22.6 million |
Growth rate | 8.5% (CAGR from 2023 to 2030) |
Largest segment | Small molecule |
Fastest growing segment | Large Molecule |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Small Molecule, Large Molecule |
Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Small molecule was the largest segment with a revenue share of 63.78% in 2024. Horizon Databook has segmented the UAE in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
The UAE has been investing significantly in developing its healthcare infrastructure, including hospitals, research centers, and clinical trial facilities. This growth in infrastructure provides a conducive environment for in vivo CROs to operate and conduct clinical trials.
Furthermore, the UAE government has been actively promoting & supporting clinical research and development activities. Initiatives such as Dubai 10X and Abu Dhabi Vision 2030 emphasize the importance of healthcare innovation and research, which fuels the demand for in vivo CRO services.
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account